Exenatide extended-release; clinical trials, patient preference, and economic considerations

References

• LigarayKPLIsleyWLDiabetes mellitus, type 2 Available from: http://emedicine.medscape.com/article/117853-overviewAccessed January 26, 2010
   Google Scholar
• KoroCEBowlinSJBourgeoisNFedderDOGlycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary reportDiabetes Care200427172014693960
   PubMed Web of Science ®Google Scholar
• ZarrinparALoombaRReview article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver diseaseAliment Pharmacol Ther20123690992123057494
   PubMed Web of Science ®Google Scholar
• DoggrellSAIs exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatideRev Recent Clin Trials20072778418473991
   PubMedGoogle Scholar
• ZinmanBHoogwerfBJDurán GarcíaSThe effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trialAnn Intern Med200714647748517404349
   PubMed Web of Science ®Google Scholar
• BuseJBBergenstalRMGlassLCUse of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trialAnn Intern Med201115410311221138825
   PubMed Web of Science ®Google Scholar
• HeineRJVan GaalLFJohnsDExenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trialAnn Intern Med200514355956916230722
   PubMed Web of Science ®Google Scholar
• BarnettAHBurgerJJohnsDTolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trialClin Ther2007292333234818158075
   PubMed Web of Science ®Google Scholar
• GailwitzEBöhmerMSegietTExenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemiaDiabetes Care20113460460621285388
   PubMed Web of Science ®Google Scholar
• DerosaGMaffioliPSalvadeoSAExenatide versus glibenclamide in patients with diabetesDiabetes Technol Ther20101223324020151774
   PubMed Web of Science ®Google Scholar
• DerosaGPutignanoPBossiACExenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patientsEur J Pharmacol201166625125621645507
   PubMed Web of Science ®Google Scholar
• BestJHHoogwerfBJHermanWHRisk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink databaseDiabetes Care201134909520929995
   PubMed Web of Science ®Google Scholar
• GargRChenWPendergrassMAcute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin – a retrospective observational pharmacy claims analysisDiabetes Care2010332349235420682680
   PubMed Web of Science ®Google Scholar
• WentenMGaeblerJAHusseinMRelative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up studyDiabet Med2012291412141822416857
   PubMed Web of Science ®Google Scholar
• RomleyJAGoldmanDPSolomonMMcFaddenDPetersALExenatide therapy and the risk of pancreatitis and pancreatic cancers in a privately insured populationDiabetes Technol Ther20121490491122845701
   PubMed Web of Science ®Google Scholar
• DeYoungMBMacConellLSarinVTrautmannMHerbertPEncapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetesDiabetes Technol Ther2011131145115421751887
   PubMed Web of Science ®Google Scholar
• FinemanMFlanaganSTaylorKPharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosingClin Pharmacokinet2011506475
   Web of Science ®Google Scholar
• KimDMacConellLZhangDEffects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetesDiabetes Care2007301487149317353504
   PubMed Web of Science ®Google Scholar
• IwamotoKNasuRYamamuraASafety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetesEndocr J20095695196219706990
   PubMed Web of Science ®Google Scholar
• DruckerDJBuseJBTaylorKExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyLancet20083721240125018782641
   PubMed Web of Science ®Google Scholar
• BuseJBDrukerDJTaylorKLDURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeksDiabetes Care2010331255126120215461
   PubMed Web of Science ®Google Scholar
• TaylorKGurneyKHanJPencekRWalshBTrautmannMExenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 yearsBMC Endocr Disord201111921529363
   PubMed Web of Science ®Google Scholar
• BlevinsTPullmanJMalloyJDURATION-5: exenatide once weekly resulted in greater improvement in glycemic control compared with exenatide twice daily in patients with type 2 diabetesJ Clin Endocrinol Metab2011961301131021307137
   PubMed Web of Science ®Google Scholar
• RidgeTMorettoTMacconellLComparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetesDiabetes Obes Metab20121410971103
   PubMed Web of Science ®Google Scholar
• PencekRBlickensderferALiYBrunellCChenSExenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulationsInt J Clin Pract2012661021103222925173
   PubMed Web of Science ®Google Scholar
• BergenstalRMWyshamCMacConellLEfficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2); a randomised trialLancet201037643143920580422
   PubMed Web of Science ®Google Scholar
• WyshamBergenstalRMalloyJDURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatideDiabet Med201128670571421434995
   PubMed Web of Science ®Google Scholar
• Russell-JonesDCuddihyRMHanefeldMEfficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug naïve patients with type 2 diabetes (DURATION-4): a 26-week double-blind studyDiabetes Care201235225225822210563
   PubMed Web of Science ®Google Scholar
• DiamantMVan GaalLStranksSNorthupJCaoDTrautmannMOnce weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trialLancet20103752234224320609969
   PubMed Web of Science ®Google Scholar
• InagakiNAtsumiYOuraTSaitoHImaokaTEfficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicentre, noninferority studyClin Ther2012341892190822884767
   PubMed Web of Science ®Google Scholar
• BuseJBNauckMForstTExenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyLancet2012pii:S0140-6736:61267
   Web of Science ®Google Scholar
• ScottDABoyeKSTimlinLClarkJFBestJHA network metaanalysis to compare glycaemic control in patients with type 2 diabetes with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily, or placeboDiabetes Obes Metab972012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• BradleyCThe Diabetes Treatment Satisfaction Questionnaire: DTSQChurBCHandbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and PracticeChur, SwitzerlandHarwood Academic Publishers1994
   Google Scholar
• KolotkinRLCrosbyRDKosloskiKDWilliamsGRDevelopment of a brief measure to assess quality of life in obesityObes Res2001910211111316344
   PubMedGoogle Scholar
• BestJHBoyeKERubinRRImproved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice dailyDiabet Med20092672272819573122
   PubMed Web of Science ®Google Scholar
• DupuyHJThe Psychological General Well-Being (PGWB) IndexWengerNKAssessment of Quality of Life in Clinical Trials of Cardiovascular TherapiesNew York, NYLeJacq Publications1984
   Google Scholar
• BestJHRubinRRPeyrotMWeight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatmentDiabetes Care20113431431921270189
   PubMed Web of Science ®Google Scholar
• FabunmiRNielsenLLQuimboRPatient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargineCurr Med Res Opin20092577778619203299
   PubMed Web of Science ®Google Scholar
• PalmerAJRozeSValentineWJThe CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-makingCurr Med Res Opin2004Suppl 1S5S2615324513
   PubMed Web of Science ®Google Scholar
• DeFronzoRARatnerREHanJEffects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesDiabetes Care2005281092110015855572
   PubMed Web of Science ®Google Scholar
• BuseJBHenryRRHanJEffects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesDiabetes Care2004272628263515504997
   PubMed Web of Science ®Google Scholar
• KendalDMRiddleMCRosenstockJEffects of exenatide (exendin-4) on glycaemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaDiabetes Care2005281083109115855571
   PubMed Web of Science ®Google Scholar
• MinshallMEOglesbyAKWintleMEValentineWJRozeSPalmerAJEstimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitusValue Health200811223318237357
   PubMed Web of Science ®Google Scholar
• GuillerminA-LLloydABestJHDeYoungMBSamyshkinYGaeblerJALong-term cost-consequence analysis of exenatide once weekly versus sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United StatesJ Med Econ20121565466322369345
   PubMedGoogle Scholar
• BeaudetAPalmerJLTimlinLCost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UKJ Med Econ20111435736621563878
   PubMedGoogle Scholar
• SamyshkinYGuillerminALBestJHBrunellSCLloydALong-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the USJ Med Econ201215Suppl 261322793669
   PubMedGoogle Scholar
• ValentineWJPalmerAJLammertMLangerJBrändleMEvaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agentsClin Ther2011331698171222018679
   PubMed Web of Science ®Google Scholar
• EddyDMSchelessingerLArchimedes – a trial-validated model of diabetesDiabetes Care2003263093310114578245
   PubMed Web of Science ®Google Scholar
• EddyDMSchelessingerLValidation of the Archimedes diabetes modelDiabetes Care2003263102311014578246
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention National Center for Health StatisticsNational Health and Nutrition Examination Survey DataHyattsville, MDUS Department of Health and Human Services, Centers for Disease Control and Prevention2010
   Google Scholar
• PeskinBRShcheprovAVBoyeKSBruceSMaggsDGGaeblerJACardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist versus. traditional therapies for type 2 diabetes: a simulation analysisDiabetes Obes Metab20111392192721624032
   PubMed Web of Science ®Google Scholar
• GaeblerJASoto-CamposGAlperinPHealth and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysisVasc Health Risk Manag2012825526422566747
   PubMedGoogle Scholar
• Home Safety MedWatchThe FDA Safety Information and Adverse Program Safety InformationByetta (exenatide) injection Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm194556.htmAccessed October 1, 2012
   Google Scholar
• SignorovitchJEWuEQSwallowEKantorEFanLGruenbergerJBComparative efficacy of vildagliptin and sitagliptin in Japanese with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trialsClin Drug Invest201131665674
   PubMed Web of Science ®Google Scholar
• BerlieHHurrneKMPinelliNRGlucagon-like peptide- 1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic reviewDiabetes Metab Syndr Obes2012516517422826635
   PubMedGoogle Scholar
• RyanDHEspelandMAFosterGDLooking AHEAD Research GroupLook AHEAD study (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetesControl Clin Trials20032461062814500058
   PubMedGoogle Scholar
• JakicicJMEganCMFabricatoreANFour-year change in cardiovascular fitness and influence on glycemic control in adults with type 2 diabetes in a randomized trial. The Look AHEAD TrialDiabetes Care1262012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• O’RiorhanMLook AHEAD trial halted Available from: http://www.medscape.com/viewarticle/772490Accessed December 13, 2012
   Google Scholar